

## Supporting Information

### **Nanoparticle Delivery of CD147 Antagonistic Peptide-9 Protects against Acute Ischemic Brain Injury and tPA-induced Intracerebral Hemorrhage in Mice**


Shan Liu<sup>1</sup>, Rong Jin<sup>1</sup>, Min Wang<sup>1</sup>, Guohong Li<sup>1\*</sup>

<sup>1</sup>Department of Neurosurgery, The Pennsylvania State University College of Medicine, Hershey, PA  
17033, USA

\* Correspondence author

Address correspondence to Dr. Guohong Li, the Neurovascular Translational Research Laboratory,  
Department of Neurosurgery, Penn State Hershey Medical Center, 500 University Drive, BMR, C3830G,  
Hershey, PA, 17033, USA. Email: [guohongli@pennstatehealth.psu.edu](mailto:guohongli@pennstatehealth.psu.edu)

No significant reduction in infarct volumes by systemic administration of naked AP9 at dose of up to 5 mg/kg.



**Figure S1. Systemic administration of naked AP9 at dose of 5 mg/kg shows no significant reduce in infarct volumes among the indicated groups 3 days after tMCAO in mice. Left, Representative images of TTC (2, 3, 5-triphenyltetrazolium chloride)-stained brain coronal sections of mice in indicated groups 3 days after tMCAO. Right, Quantitative analysis of infarct volumes. n.s. indicates not statistically significant.**